Skelton Laurence Matthew 4

4 · Vera Therapeutics, Inc. · Filed Feb 6, 2026

AI-generated summary of this filing

Updated Feb 7, 2026

Vera Therapeutics CCO Laurence Skelton Receives 60,000-Share Awards

What Happened

Laurence Matthew Skelton, Chief Commercial Officer of Vera Therapeutics (VERA), received equity awards on 2026-02-04 totaling 60,000 shares: 20,000 restricted stock units (RSUs) and rights to 40,000 derivative shares (stock option/award). Both grants show an acquisition price of $0, so no cash was paid by the insider. These are awards (transaction code A), not open-market purchases or sales.

Key Details

Transaction date: 2026-02-04. Filing date (Form 4): 2026-02-06 (timely filing).
Price: $0.00 per share for both the 20,000 RSUs and the 40,000 derivative award (total reported value = $0 on grant).
Shares owned after transaction: Not specified in the provided filing details.
Footnote F1 (RSUs): 20,000 RSUs vest 25% each year on Feb 20 of 2027, 2028, 2029 and 2030, subject to continued service.
Footnote F2 (derivative): 40,000-share award vests 1/48th on March 4, 2026 and then monthly 1/48th thereafter, subject to continued service (standard time-based vesting).
Transaction type: Award/grant (A). No sale, purchase, or immediate exercise/sale noted.

Context

RSUs represent a promise to deliver shares on vesting; the derivative award is a time-vesting equity right (likely options) that vests monthly. Neither transaction provides immediate liquidity and both are typical components of executive compensation programs. The filing does not indicate any sale or cashless exercise tied to these awards.

Form 4

Period: 2026-02-04

Chief Commercial Officer

Transactions

Award
Class A Common Stock
[F1]
2026-02-04+20,000→ 65,800 total
Award
Stock Option (right to buy)
[F2]
2026-02-04+40,000→ 40,000 total
Exercise: $42.74Exp: 2036-02-03→ Class A Common Stock (40,000 underlying)

Footnotes (2)

[F1]Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs") granted under the Issuer's 2021 Equity Incentive Plan. One-fourth of the RSUs, rounded to the nearest whole share, vest on each of February 20, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continuous service through each vesting date.
[F2]1/48th of the shares subject to the stock option will vest and become exercisable on March 4, 2026, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date.

Signature

/s/ Joseph R. Young, Attorney-in-Fact|2026-02-06

1 file